Related Experiment Video
Updated: Aug 8, 2026
15:57
Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle
Published on: July 11, 2015
[Specific interferon-gamma assays: a modern tool for tuberculosis diagnosis]
F Luarti Ruiz1, R Audran, A Harari
1Service d'immunologie et allergie, CHUV, 1011 Lausanne. floriana.lurati@chuv.ch
Revue Medicale Suisse
|May 23, 2006
Summary
Interferon-gamma release assays (IGRAs) offer higher specificity for latent tuberculosis diagnosis than the tuberculin skin test. These tests reduce false positives, improving patient outcomes and healthcare efficiency.
Area of Science:
- Immunology
- Infectious Diseases
- Diagnostic Medicine
Context:
- Latent tuberculosis diagnosis presents challenges with traditional methods like the tuberculin skin test (TST).
- BCG vaccination and non-tuberculous mycobacterial infections can lead to false positives with TST.
- Accurate diagnosis is crucial to prevent unnecessary treatment and associated side effects.
Purpose:
- To evaluate the diagnostic performance of antigen-specific interferon-gamma assays (IGRAs) compared to TST for latent tuberculosis.
- To assess the specificity, correlation with exposure, and cross-reactivity of IGRAs.
Summary:
- IGRAs utilizing ESAT-6 and CFP-10 antigens demonstrate superior specificity for latent tuberculosis compared to TST.
- These assays show better correlation with Mycobacterium tuberculosis exposure and reduced cross-reactivity from BCG vaccination or non-tuberculous mycobacteria.
- Fewer false positives with IGRAs minimize unnecessary treatment costs and potential adverse effects.
Impact:
- IGRAs are valuable additions to tuberculosis diagnostic algorithms, especially in low-endemic areas.
- Reduced false positives improve patient management and resource allocation in healthcare.
- Further research is needed to explore IGRA utility in specific patient groups and as a disease activity marker.
